Clinical trials: Nonsmall Cell Lung Cancer Stage III
Superior Sulcus Tumor, Non-small Cell Lung Cancer Stage IIB
Efficacy and Safety of CRT, Durvalumab and Surgery for SST
The safety and efficacy of multimodality treatment of pre- and post-operative durvalumab therapy after pre-operative chemoradiotherapy for resectable superior sulcus tumor (SST) and durvalumab maintenance therapy after…
- Conditions
- Superior Sulcus Tumor, Non-small Cell Lung Cancer Stage IIB, Non Small Cell Lung Cancer Stage III
- Trial name
- DEEP_OCEAN (NCT04465968)
- Testing
- Cisplatin, S1, concurrent radiotherapy
- Volunteers
- 84 people
- Sponsor
- National Cancer Center Hospital East
Non-Small Cell Lung Cancer
Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation
This 2 arm study will compare the efficacy and safety of treatment with erlotinib intercalated with platinum-based therapy or erlotinib along, as first line treatment in Stage IIIB/IV Non-Small Cell Lung Cancer Patients With…
- Trial name
- NCT02001896
- Testing
- gemcitabine; cisplatin or carboplatin; erlotinib, erlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xinjiang Medical University
First Line Non-Small Cell Lung Cancer
Avelumab in First-line NSCLC (JAVELIN Lung 100)
The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in…
- Trial name
- NCT02576574
- Testing
- Avelumab, Pemetrexed, Paclitaxel
- Where
- 349 sites in United States, Australia and 40 more
- Volunteers
- 1,214 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non-small Cell Lung Cancer, Stage III
Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)
For patients with stage III Lung Cancer, We propose one cycle chemotherapy using Abraxane and Carboplatin, followed by pulsed low-dose sensitizing Abraxane chemotherapy and daily Radiation.
- Trial name
- NCT00903942
- Testing
- radiation therapy, Paclitaxel Protein-Bound, and CARBOPLATIN
- Where
- United States
- Sponsor
- University of Rochester
Non Small Cell Lung Cancer
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
This single-arm phase 2 study will enroll patients with resectable and operable stage IB - III non-small cell lung cancer and treat them with pre-operative ipilimumab + nivolumab plus low-dose stereotactic body radiation therapy…
- Trial name
- NCT04933903
- Testing
- Ipilimumab, Nivolumab, SBRT
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Brown University
Lung Cancer
Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
This randomized phase III trial is studying carboplatin, paclitaxel, radiation therapy, and thalidomide to see how well they work compared to carboplatin, paclitaxel, and radiation therapy alone in treating patients with newly…
- Trial name
- NCT00004859
- Testing
- carboplatin, paclitaxel, thalidomide
- Where
- 236 sites in United States, South Africa
- Volunteers
- 589 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00023673
- Testing
- carboplatin, paclitaxel, three-dimensional conformal radiation therapy
- Where
- 41 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Radiation Therapy Oncology Group
Non Small Cell Lung Cancer
Dynamics of 18-FDG Uptake in Stage III/IV Non Small Cell Lung Cancer During First Line Pembrolizumab Treatment
The aim of this study is to describe the early dynamics of 18-FDG uptake in non smal cell lung cancer during first line treatment with pembrolizumab, and to evaluate whether or not they differ according to treatment response at 3…
- Trial name
- iTEP1 (NCT03832348)
- Testing
- PET scan imaging
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Henri Becquerel
Gastrinoma, Glucagonoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00655655
- Testing
- everolimus, vatalanib, pharmacological study
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Non Small Cell Lung Cancer
A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC
The goal of this prospective, observational study is to explore the value of dynamic monitoring of minimal residual lesions in driver mutated stage III NSCLC for disease recurrence and prognosis assessment.
- Trial name
- NCT06443684
- Testing
- MRD
- Where
- 14 sites in China
- Volunteers
- 305 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing.
- Trial name
- NCT00006049
- Testing
- carboplatin, gefitinib, paclitaxel
- Where
- United States
- Sponsor
- AstraZeneca
Stage III Non-small-cell Lung Cancer
Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung
Durvalumab is a drug that stimulates the immune system to fight lung cancer. Durvalumab is FDA approved to treat lung cancer. Stereotactic body radiation therapy (SBRT) is a newer radiation treatment that gives fewer, but higher…
- Trial name
- 358 (NCT03589547)
- Testing
- Durvalumab, SBRT
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brown University
Lung Cancer
Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether polyglutamate paclitaxel is more effective than docetaxel in treating non-small…
- Trial name
- NCT00054184
- Testing
- docetaxel, paclitaxel poliglumex
- Where
- 35 sites in United States
- Volunteers
- 350 people
- Sponsor
- CTI BioPharma
NSCLC, Stage III
Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.
To compare a complex induction multimodality protocol (ESPATUE) + concurrent immunotherapy with PD-L1 antibody Durvalumab given every three weeks to the same induction multimodality protocol without Durvalumab immunotherapy…
- Trial name
- ESPADURVA (NCT04202809)
- Testing
- Durvalumab
- Where
- 7 sites in Germany
- Volunteers
- 90 people
- Sponsor
- University Hospital, Essen
Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
The study aims to explore the prevalence of ALK/ROS1/MET mutations assessed with ctDNA samples in EGFR-wildtype NSCLC
- Conditions
- Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic, Adenocarcinoma of Lung, EGFR Wildtype
- Trial name
- NCT02946216
- Testing
- ctDNA analysis
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First People's Hospital of Hangzhou
Non-small Cell Lung Cancer
Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
This study was designed to determine whether adjuvant vinorelbine plus cisplatin and endostar prolongs overall survival compare to vinorelbine plus cisplatin alone among patients with completely resected IB-IIIA non-small-cell…
- Trial name
- NCT00576914
- Testing
- recombinant human endostatin
- Where
- China
- Volunteers
- 1,108 people
- Sponsor
- Chinese Academy of Sciences
Melanoma Stage III, Melanoma Stage IV
Appropriate Dosing to Optimise Personalised Cancer Treatments
This is a pilot study to assess feasibility of dried blood spot (DBS) samples for pharmacokinetic measurements of targeted anti-cancer drugs in oncology patients such as patients with BRAF-mutant melanoma receiving targeted…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Ovarian Cancer, Renal Cancer Stage III
- Trial name
- ADOPT (NCT04154163)
- Testing
- Dried blood Spot (DBS), Venous blood sampling
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- University of Dundee
Lung Neoplasms
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer
Primary Objective: Response rate (by contrast CT scan) Secondary Objectives: Progression-free survival (PFS) Overall survival (OS)
- Trial name
- C-CRISP (NCT01266512)
- Testing
- DOCETAXEL, Intensity Modulated Radiotherapy (IMRT), CISPLATIN
- Where
- Hong Kong
- Volunteers
- 34 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy
The "PACIFIC" trial confirmed that the consolidation therapy with durvalumab in patients with stage III, locally advanced, unresectable NSCLC that had not progressed after definitive platinum-based chemoradiation therapy improved…
- Conditions
- Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
- Trial name
- PLATINUM (NCT05338619)
- Testing
- Lazertinib
- Where
- 13 sites in South Korea
- Volunteers
- 77 people
- Sponsor
- Sung Yong Lee
Lung Cancer (NSCLC)
Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations
This study evaluates the effectiveness and safety of targeted therapy given before and after surgery in patients with resectable or potentially resectable stage III non-small cell lung cancer with selected genetic alterations.
- Trial name
- NCT07829744
- Testing
- Surgical Resection
- Volunteers
- 190 people
- Sponsor
- Shanghai Zhongshan Hospital